Get the app
US › Healthcare

InflaRx N.V. (IFRX)

US · Healthcare · Biotechnology

$1.32-8.33%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-10.6M
EPS
$-0.11
EPS estimate
$-0.08

EPS came in at -0.11 against a street estimate of -0.08 — a miss of 37.5%.

Key statistics

Market cap
$235.8M
Forward P/E
0.0
P/B
1.72
Book value
$1.12
EPS (TTM)
$-0.58
52-week high
$2.95
52-week low
$0.80
50-day MA
$1.98
200-day MA
$1.60
Beta
2.61

Analyst view

Analysts rate InflaRx N.V. a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $7.71.

Shareholding

Insiders
2.95%
Institutions
70.34%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC15.56%
TCG Crossover Management, LLC9.84%
FMR Inc5.54%
COMMODORE CAPITAL LP4.95%
Kalehua Capital Management LLC3.93%
Spruce Street Capital LP3.63%
Farallon Capital Management, L.L.C.2.26%
683 Capital Management LLC2.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InflaRx N.V. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.